Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases

GAITHERSBURG, MD and CAMBRIDGE, MA, July 31, 2003 MedImmune, Inc. (Nasdaq: MEDI) and Critical Therapeutics, Inc. (CTI), a private biopharmaceutical company, today announced the signing of an agreement to co-develop biologic products targeting a novel pro-inflammatory cytokine to treat severe inflammatory diseases.

MedImmune and CTI will collaborate on the research and development of antibodies and other drug products targeting the High Mobility Group Box Chromosomal Protein 1 (HMGB-1), which is believed to be involved in the tissue damage associated with a range of inflammatory illnesses, such as rheumatoid arthritis and sepsis. The companies plan to focus on developing drug products with the potential to block HMGB-1, which if successful, could help reduce the injury and death associ-ated with severe inflammatory diseases and infections.

"CTI's proprietary anti-HMGB-1 technology is a great fit with our core expertise in antibody technology and anti-arthritic/anti-inflammatory disease research," commented James F. Young, Ph.D., MedImmune's president of research and development. "Elevated levels of HMGB-1 are found in many acute and chronic diseases, including rheumatoid arthritis, inflammatory bowel disease, hemorrhagic shock, sepsis, endotoxemia, and acute lung injuries. We believe that treat-ment with anti-HMGB-1 antibodies or antagonists may help alleviate or prevent the severe tissue damage that often results from such afflictions."

HMGB-1 is a cytokine, which means it is one of the many hormone-like proteins secreted by dif-ferent cell types that regulate the intensity and duration of an immune response. HMGB-1 is ex-pressed at high levels beginning approximately 12 to 72 hours after an inflammatory reaction of the immune system has been initiated and at about the time tissue damage is believed to occur. Because of the timing and the duration of its expression, HMGB-1 could potentially be a more important factor than other cytok

Contact: Scott Solomon
Sharon Merrill Associates, Inc.

Page: 1 2

Related biology news :

1. Critically endangered monkey species plummets more than 50 percent since 1994
2. Save The Tiger Fund announces alliance with the Critical Ecosystem Partnership Fund
3. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
4. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
5. Critical early-defense trigger in plants found
6. Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease
7. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
8. Study Furthers Understanding Of Critical Alzheimers Disease Gene
9. Gene Once Thought To Program Ovarian Development Instead Found To Be Critical For Production Of Sperm
10. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
11. Columbia Researchers Synthesize Compound With Possible Link To MacularDegeneration; Work Is Critical To Pinpointing Causes Of Disease, Scientists Say

Post Your Comments:

(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: